Attovia Therapeutics, Inc. Common Stock (ATTO) Stock
Key stats
- Market cap
- $764.77M
- Price / Earnings ratio
- -12.5x
- EPS (TTM)
- -$15.42
- Volume
- Loading
- 52-week high
- $28.00
- 52-week low
- $12.94
Source: third-party data provider, as of November 13, 2026
Compare with ATTO
Recent news
Meet Attovia: The Clinical-Stage Biotech That Aims to Stop Chronic Itch at the Source
Meet Attovia: The Clinical-Stage Biotech That Aims to Stop Chronic Itch at the Source
ATTO
Goldman Sachs-backed Attovia eyes $731.5 million valuation in upsized US IPO
Goldman Sachs-backed Attovia eyes $731.5 million valuation in upsized US IPO
ATTOTechnical indicators
- RSI 14
- 56.01
- MACD 12/26/9
- -0.23
- EMA 9 of MACD
- -0.63
- MACD histogram
- 0.40
- SMA 50
- $17.86
- Price below SMA 50
- EMA 50
- $17.38
- Price below EMA 50
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news
Meet Attovia: The Clinical-Stage Biotech That Aims to Stop Chronic Itch at the Source
Meet Attovia: The Clinical-Stage Biotech That Aims to Stop Chronic Itch at the Source
ATTOGoldman Sachs-backed Attovia eyes $731.5 million valuation in upsized US IPO
Goldman Sachs-backed Attovia eyes $731.5 million valuation in upsized US IPO
ATTOAbout Attovia Therapeutics, Inc. Common Stock
Attovia Therapeutics is a clinical-stage biopharmaceutical developer focused on next-generation biotherapeutics for immune-mediated diseases with high unmet need. Its lead pipeline candidates target commercially validated pathways and are designed through the proprietary ATTOBODY biologics platform to deliver improved treatments relative to current standards of care.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Tao Fu M.B.A., M.S. | CEO, President & Director | 1972 |
| Mr. Steven Chan CPA | Chief Financial Officer | 1972 |
| Dr. Petter Veiby Ph.D. | Chief Scientific Officer | 1965 |
| Dr. Hubert C. Chen M.D., M.P.H. | Chief Medical Officer | 1969 |
| Dr. Hangjun Zhan Ph.D. | Chief Technology Officer | 1960 |
| Dr. Bora Han Ph.D. | VP & Head of Preclinical Development | — |
| Dr. Zaneta Odrowaz Ph.D. | Chief Business Officer, Treasurer & Secretary | 1984 |
Fundamentals
Valuation
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 56.01
- MACD 12/26/9
- -0.23
- EMA 9 of MACD
- -0.63
- MACD histogram
- 0.40
- SMA 50
- $17.86
- Price below SMA 50
- EMA 50
- $17.38
- Price below EMA 50
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $34.00
- Average
- $42.75
- High
- $52.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -11.8 | +8.3 | ||||||||||
| 2022 | -15.8 | +4.1 | +9.5 | -9.2 | -57.6 | -4.9 | -10.1 | -38.1 | -25.9 | -32.0 | +105.1 | -24.5 |
| 2023 | +22.5 | -51.9 | -22.4 | -10.9 | +51.4 | -63.4 | -17.5 | |||||
| 2026 | -2.3 | -22.9 | -14.6 | +10.6 |
